Goldman Sachs is to cease coverage of struggling Endo International plc. The move follows the US-based firm guiding for its adjusted EBITDA to fall by as much as 65% quarter-over-quarter in the wake of generic competition to its $900m Vasostrict (vasopressin) injectable.
The New York-based investment bank typically publishes a report of Endo’s quarterly financial results and other material events